Ge Long Hui·2026-02-11 10:27Core Viewpoint - Ribocure Pharmaceuticals AB, a subsidiary of Ribocure Bio-B (6938.HK), has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals, Inc. for the development of six clinical-stage small interfering RNA (siRNA) therapies targeting metabolic dysfunction-related fatty liver disease (MASH) [1] Group 1 - The agreement grants Madrigal exclusive global rights to utilize Ribocure's RiboGalSTAR and siRNA chemical modification platforms for the development, production, and commercialization of several clinical-stage single-target and dual-target siRNA assets [1] - Ribocure will receive an upfront payment of $60 million, with potential cumulative payments of up to $4.4 billion upon achieving various development, regulatory, and commercialization milestones, in addition to potential royalties on net sales [1] - This collaboration leverages the company's proven liver-targeting RiboGalSTAR platform to develop new therapies for MASH, marking a significant milestone in the company's path to becoming a leading global innovator in siRNA [1]